Cardiac clinical trials are research studies through which improvements in the prevention, detection and treatment of heart disease are tested.
Clinical trials evaluate new drugs, devices and procedures that are not yet available to the public. By participating in a clinical trial, you may have early access to these treatments before they become widely available, and you can directly contribute to the advancement of medical research.
Numerous studies have demonstrated better clinical outcomes for clinical trial participants irrespective of treatment allocation (active intervention or control group) because of the expert monitoring and treatment they receive as part of the clinical trial.
If you are interested in finding out more about participating in any of our current trials, please contact us at ISLHD-cardiacresearch@health.nsw.gov.au or (02) 4253 4908.
Current trials – 2023
Illawarra Heart Health Centre - Cardiovascular Clinical Trials (intervention) |
|||
|
Trial Name |
Full Title |
Principal Investigator |
Status |
|
EASY-AS |
A trial of early valve replacement in severe asymptomatic aortic stenosis. |
Dr Danson |
Open to recruitment |
|
TCC-Cardiac |
The TCC study examines the efficacy of a smartphone application in patients with a recent acute cardiac event (heart attack or heart failure) |
Dr Shetty |
Open to recruitment |
|
GOAL-ASIA |
The GOAL-ASIA study aims to engage and empower patients to know their cholesterol levels, understand the medications they're on to lower it, and to help them reach their goals by knowing their targets. |
A/Prof Lee |
Open to recruitment |
|
OCEAN |
Assess Prevalence of raised lipoprotein (a), a marker for cardiovascular disease, in patients with CVD (MI or stent) |
A/Prof Lee |
Open to recruitment |
Cardiovascular Clinical Trials (medication) |
|||
|
Trial Name |
Full Title |
Principal Investigator |
Status |
|
ZEUS |
Ziltivekimab (anti-inflammatory monoclonal antibody) versus placebo in patients with cardiovascular disease, renal impairment and raised hs-CRP. |
A/Prof Lee |
Open to recruitment |
|
PREVAIL |
Obicetrapib versus placebo in participants with Atherosclerotic Cardiovascular Disease whose cholesterol levels remain elevated despite Maximally Tolerated Lipid-Modifying Therapies. |
A/Prof Lee |
Open to recruitment |
|
OCEAN (a) |
Olpasiran versus placebo in patients with Atheroclerotic Cardiovascular Disease and Elevated Lipoprotein (a) (CV outcome study) |
A/Prof Lee |
Open to recruitment |
|
OCEANIC-AF |
Asundexian versus Apixaban in patients with Atrial Fibrillation. (Stroke prevention) |
A/Prof Lee |
Open to recruitment |